EX-99.1 2 nstg-qrtlyx8kex991pressrel.htm EXHIBIT 99.1 Exhibit



Exhibit 99.1
nstg-logoa02.jpg

NanoString Technologies Releases Operating Results for Third Quarter of 2019
SEATTLE - November 4, 2019 - NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of 2019.
Third Quarter Financial Highlights
•
Total product and service revenue of $26.3 million, 23% year-over-year growth
•
Instrument revenue of $8.0 million, including $2.2 million of GeoMx™ DSP instrument revenue, 48% year-over-year growth
•
Consumables revenue of $15.3 million, including $2.5 million of Prosigna® IVD kits, 11% year-over-year growth
•
Service revenue of $3.1 million, 31% year-over-year growth
•
Collaboration revenue recognized of $4.3 million and cash received from collaborators of $4.5 million
•
Updated fiscal 2019 product and service revenue guidance to $100 to $103 million from the previous range of $98 to $103 million, which includes GeoMx DSP revenue guidance at the top end of the previous range
“During the third quarter we achieved the seventh consecutive quarter of double-digit revenue growth in our core nCounter® business, driven by strong instrument placements and an expanded consumable portfolio,” said Brad Gray, president and CEO of NanoString. “The shipment of our first commercial GeoMx DSP instruments during the third quarter accelerated our instrument revenue growth to more than 40%, and we see positive leading indicators of GeoMx interest including record demand for our GeoMx Technology Access Program.”
Recent Business Highlights
nCounter Platform
•
Increased installed base to approximately 820 nCounter Analysis Systems at September 30, 2019, as compared to approximately 695 systems at September 30 in the prior year.
•
Surpassed 2,800 cumulative peer-reviewed publications of studies utilizing nCounter technology.
•
Launched nCounter Human Organ Transplant Panel to study the mechanisms of organ rejection and to monitor the toxicities of immunosuppressive drugs and viral infections.
GeoMx Digital Spatial Profiling (DSP) Platform
•
Received orders for more than 15 additional GeoMx DSP systems, bringing cumulative orders to more than 70 systems.
•
Shipped our first ten commercial GeoMx DSP systems during the quarter.
•
Completed more than 40 GeoMx DSP Technology Access Program (TAP) projects during the third quarter, expanding the total number of projects completed to approximately 170 projects for about 110 unique customers.
•
GeoMx DSP featured on the cover of the September issue of Clinical Cancer Research, highlighting an article describing research by Dr. David Rimm et al. from Yale University using GeoMx DSP (see accompanying image).
•
First peer-reviewed publication demonstrating the utility of GeoMx DSP in Neuroscience research.
Leadership
•
Announced the appointment of Mark Winham as senior vice president of Operations. Mr. Winham was previously vice president of Global Manufacturing for Life Technologies.
•
Announced the appointment of Don Kania, Ph.D. to the Company’s Board of Directors. Dr. Kania was previously the CEO and president of FEI, a leading electron microscopy company.
Third Quarter Financial Results
Product and service revenue for the three months ended September 30, 2019 increased by 23% to $26.3 million, as compared to $21.5 million for the third quarter of 2018. Instrument revenue was $8.0 million, an increase of 48% compared to the prior year period. Consumables revenue, excluding Prosigna, was $12.7 million, an increase of 14% compared to the prior year period, with growth driven primarily by sales of our panel products. Prosigna IVD kit revenue remained flat at $2.5 million as compared to the prior year period. Service revenue was $3.1 million, an increase of 31% compared to the prior year period, reflecting continued growth in demand for our GeoMx DSP Technology Access Program and an increased number of service contracts associated with our growing installed base of nCounter instruments. Gross margin on product and service revenue was 59% compared to 57% in the prior year period, reflecting a mix shift towards our MAX and FLEX nCounter instruments as well as sales of our new GeoMx DSP instruments.
Collaboration revenue totaled $4.3 million, compared to $7.2 million for the prior year period, and was derived primarily from our collaboration with Lam Research. Cash received from collaborators totaled $4.5 million during the quarter, primarily reflecting activity relating to our collaboration with Lam Research and the remaining activities for our Celgene collaboration, which ended during the second quarter of this fiscal year.
Research and development expense increased by 2% to $17.0 million compared to $16.7 million for the prior year period, primarily due to higher stock-based compensation expense. Selling, general and administrative expense increased by 31% to $23.4 million compared to $17.8 million for the prior year period, primarily reflecting increased investment in personnel and commercial launch activities related to GeoMx DSP and higher stock-based compensation expense.
Net loss was $22.7 million, or a loss of $0.64 per share, compared with $16.5 million, or $0.56 per share, for the prior year period.
Outlook for 2019
The company updated its revenue and gross margin guidance for fiscal 2019, with results expected as follows:
•
Product and service revenue of $100 million to $103 million, including approximately $8 million of revenue recorded from sales of GeoMx DSP, as compared to previous guidance of $98 million to $103 million and $6 to $8 million respectively.
•
Total revenue of $121 million to $124 million, which includes product and service revenue plus approximately $21 million of collaboration revenue, as compared to previous guidance of $118 million to $123 million and approximately $20 million respectively.
•
Gross margin on product and service revenue of 58% to 59%, as compared to previous guidance of 57% to 59%.
The company also updated its guidance for certain operating expenses and other items. These updates reflect additional investments directed to capture demand for and support the launch of GeoMx DSP, as well as higher expected stock-based compensation expense. For the full year 2019, the company now expects:
•
Selling, general and administrative expenses of $92 million to $93 million, as compared to previous guidance of $85 million to $87 million.
•
Research and development expenses of $66 million to $67 million, as compared to previous guidance of $64 million to $66 million, to be partially offset by approximately $20 million expected to be received from Lam Research.
•
GAAP net loss of $85 million to $87 million, as compared to previous guidance of $78 million to $83 million.
•
Net loss per share of $2.40 to $2.50, as compared to previous guidance of $2.20 to $2.40, reflecting the collective impact of the updates described above and the impact of additional shares issued in the offering of common stock completed in March 2019.
Conference Call
Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Individuals interested in listening to the conference call may do so by dialing (866) 211-0364 for domestic callers, or (647) 689-6861 for international callers. Please reference Conference ID 9358402. To listen to a live webcast, please visit the investor relations section of the company’s website at www.nanostring.com. A replay of the call will be available beginning November 4, 2019 at 7:30pm ET through midnight ET on November 11, 2019. To access the replay, dial (800) 585-8367 or (416) 621-4642 and reference Conference ID: 9358402. The webcast will also be available on the company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 2,800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for future revenue growth, the impact of new products and expansion into new markets, the company’s anticipated uses or sources of cash, the growth trajectory of the company’s nCounter and GeoMx DSP systems, the anticipated demand for new platforms, the anticipated benefits of the company’s collaboration relationships, the timing of development funding and the company’s estimated 2019 operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString logo, NanoString, NanoString Technologies, GeoMx, Hyb & Seq, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions. All other trademarks are the property of their respective owners. All rights reserved.
Contact    
Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768





NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
 
Three Months Ended
September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Revenue:
 
 
 
 
 
 
 
Instruments
$
8,037

 
$
5,429

 
$
17,295

 
$
15,591

Consumables
12,736

 
11,140

 
36,656

 
30,778

In vitro diagnostic kits
2,517

 
2,547

 
7,445

 
7,234

Services
3,059

 
2,337

 
8,673

 
6,279

Total product and service revenue
26,349

 
21,453

 
70,069

 
59,882

Collaboration
4,255

 
7,163

 
18,568

 
16,818

Total revenue
30,604

 
28,616

 
88,637

 
76,700

Costs and expenses:
 
 
 
 
 
 
 
Cost of product and service revenue
10,925

 
9,291

 
29,239

 
25,538

Research and development
17,007

 
16,651

 
50,063

 
45,068

Selling, general and administrative
23,382

 
17,810

 
69,317

 
57,897

Total costs and expenses (a) (b)
51,314

 
43,752

 
148,619

 
128,503

Loss from operations
(20,710
)
 
(15,136
)
 
(59,982
)
 
(51,803
)
Other income (expense):
 
 
 
 
 
 
 
Interest income
763

 
384

 
2,114

 
826

Interest expense
(2,415
)
 
(1,631
)
 
(6,052
)
 
(4,798
)
Other expense, net
(322
)
 
(46
)
 
(552
)
 
(330
)
Total other expense, net
(1,974
)
 
(1,293
)
 
(4,490
)
 
(4,302
)
Net loss before provision for income taxes
(22,684
)
 
(16,429
)
 
(64,472
)
 
(56,105
)
Provision for income taxes
(64
)
 
(57
)
 
(211
)
 
(185
)
Net loss
$
(22,748
)
 
$
(16,486
)
 
$
(64,683
)
 
$
(56,290
)
Net loss per share, basic and diluted
$
(0.64
)
 
$
(0.56
)
 
$
(1.90
)
 
$
(2.09
)
Shares used in calculating basic and diluted net loss per share
35,576

 
29,366

 
34,121

 
26,882

 
 
 
 
 
 
 
 
(a) Includes $4.7 million and $2.8 million of stock-based compensation expense for the three months ended September 30, 2019 and 2018, respectively, and $12.7 million and $8.7 million for the nine months ended September 30, 2019 and 2018, respectively.
(b) Includes $1.2 million and $1.0 million of depreciation and amortization expense for the three months ended September 30, 2019 and 2018, respectively, and $3.6 million and $3.0 million for the nine months ended September 30, 2019 and 2018, respectively.
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
 
September 30,
 
December 31,
 
2019
 
2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
23,442

 
$
24,356

Short-term investments
105,423

 
69,641

Accounts receivable, net
19,542

 
17,279

Inventory, net
19,040

 
13,173

Prepaid expenses and other
10,877

 
7,258

Total current assets
178,324

 
131,707

Property and equipment, net
14,863

 
15,171

Operating lease right-of-use assets
25,344

 
—

Other assets
2,228

 
680

Total assets
$
220,759

 
$
147,558

Liabilities and Stockholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
6,724

 
$
8,636

Accrued liabilities
5,632

 
3,705

Accrued compensation and other employee benefits
10,774

 
12,060

Customer deposits
6,462

 
8,167

Deferred revenue, current portion
4,389

 
9,890

Deferred rent, current portion
—

 
657

Operating lease liabilities, current portion
3,690

 
—

Total current liabilities
37,671

 
43,115

Deferred revenue, net of current portion
876

 
1,620

Deferred rent and other long-term liabilities, net of current portion
246

 
7,558

Long-term debt, net of discounts
79,194

 
58,396

Operating lease liabilities, net of current portion
30,183

 
—

Total liabilities
148,170

 
110,689

Total stockholders’ equity
72,589

 
36,869

Total liabilities and stockholders’ equity
$
220,759

 
$
147,558